Compare Amphastar Pharmaceuticals Inc (AMPH) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Live Nation Entertainment, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Live Nation Entertainment, Inc. trades at $183.51 (market cap $41.84B). The key difference: Live Nation Entertainment, Inc. is far larger — about 50.6× Amphastar Pharmaceuticals Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | LYV | |
|---|---|---|
Market Cap | $826.08M | $41.84B |
Sector | Health | Industrials |
52-Week High | $30.81 | $186.59 |
52-Week Low | $16.87 | $125.61 |
Enterprise Value | $1.22B | $43.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Live Nation (LYV) trades at $179.79, down 1.53% today, with strong analyst support (88.6% buy ratings) and a $200.20 consensus price target. The stock shows bullish technical signals despite recent earnings misses, with revenue growth to $25.2B in 2025 but net margins narrowing to 1.96%. Recent news highlights strong concert demand and strategic initiatives, though legal challenges and cost pressures remain concerns.
Outlook remains positive based on analyst consensus and projected cash flow growth, but investors face risks from volatile earnings, high debt levels, and regulatory scrutiny. The stock's elevated P/E of 117.5 reflects growth expectations that must materialize to justify current valuations amid competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
